# A-06 — Ivermectin

The strongest single-agent evidence base in this register: two trials, 1,371 subjects, and 519 people followed for about a year.

- **Canonical:** https://www.30plusskin.care/actives/ivermectin
- **Site:** 30+/SKIN — Skincare, published as a spec sheet.
- **Issue:** ISSUE NO. 13 / REV. 2026.10
- **Standing terms:** INDEPENDENT · AFFILIATE-FUNDED · NOT MEDICAL ADVICE

---

## Datasheet

- **INN / INCI:** Ivermectin
- **Family:** Avermectin — antiparasitic and anti-inflammatory
- **Molecular weight:** 875.10 g/mol
- **Layer reached:** EPIDERMIS
- **Prescription only:** yes
- **Evidence grade:** A
- **Controlled trials on file:** 2
- **Strength range recorded:** 0.88%–1%
- **Representative reference concentration:** 1%
- **Irritation (0–10):** 2
- **Onset:** 4–12 WK
- **Stability:** STABLE

## Mechanism

The concentration marker is not a recommended dose or a claim that other strengths are untested. Compare the vehicle, indication and trial population.

Reduces Demodex density and moderates the inflammatory response to it, with independent anti-inflammatory activity on the innate immune pathways implicated in rosacea.

## Measured endpoints

| Endpoint | Effect vs comparator | Window | Record |
| --- | --- | --- | --- |
| IGA clear or almost clear | +26.8% | 12 WK | REF-05 — Soolantra — study 1, inflammatory lesions of rosacea (Randomised, vehicle-controlled, co-primary endpoints, n=683, grade A) |
| Inflammatory lesion reduction | +22.3% | 12 WK | REF-06 — Soolantra — study 2, inflammatory lesion counts (Randomised, vehicle-controlled, co-primary endpoints, n=688, grade A) |

## Layering

- **Do not layer with:** Eyes and mucous membranes
- **Pairs with:** Azelaic acid, Metronidazole, Daily sunscreen

## Notes

- Adverse reactions were reported in 1% or fewer of subjects treated for at least three months — the lowest reaction profile in this register, on skin that is intolerant by definition.
- The safety cohort runs to 519 subjects at approximately one year. Every compounded rosacea product here is sold as an indefinite subscription with no long-term data at all.
- It treats papules and pustules. Nothing in it addresses persistent erythema or telangiectasia.
- Found compounded at 0.88% — 88% of the strength that produced these results, with nothing published about what the other 12% was worth.

## Products in the register containing it

| No. | Product | Stance | Score | Document |
| --- | --- | --- | --- | --- |
| R-40 | Galderma Soolantra | RECOMMENDED | 82/100 | /reviews/soolantra-ivermectin-cream-review |
| R-33 | Alloy Rosacea Face Cream Rx | CONDITIONAL | 70/100 | /reviews/alloy-rosacea-face-cream-review |
| R-24 | Dermatica Rosacea Treatment | CONDITIONAL | 71/100 | /reviews/dermatica-rosacea-review |

---

## PROMOTIONAL SPOTLIGHT: Explore CoreAge Rx skincare

More options for your skin. A patient community to connect with along the way.

**Five skincare options to explore** — Browse CoreAge Rx's prescription skincare range for concerns including fine lines, dark spots, blemishes and more.

**Connect with other patients** — Explore the CoreAge Rx patient community for shared experiences, conversations and support beyond your daily routine.

[CHECK OUT COREAGE RX SKINCARE](https://try.coreagerx.com/skincare?utm_source=30plusskin.care&utm_medium=affiliate&utm_campaign=skincare_reviews&utm_content=reading_footer)

[EXPLORE THE PATIENT COMMUNITY](https://community.coreagerx.com/)

[Read our CoreAge Rx reviews](/reviews/coreage-rx-skincare-review)

Prescription options require a clinician's assessment. Compounded medications are not FDA-approved. Community discussions do not replace medical advice.

[Product range](https://help.coreagerx.com/medication/coreage-rx-prescription-skincare) · [Community information](https://www.coreagerx.com/contact-us/)

[About promotional placements](/disclosure)

---

## Elsewhere in the register

- [Review register](/reviews)
- [Active monographs](/actives)
- [Brand register](/brands)
- [Evidence register](/evidence)
- [The ledger](/ledger)
- [How we test](/how-we-test)
- [Agent guide](/llms.txt)
- [Sitemap](/sitemap.xml)

_SOURCE-BASED ASSESSMENTS. PUBLISHER PREFERENCES ARE IDENTIFIED SEPARATELY._